Loading…
Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes. Diabetic macroangiopathies, particularly cardiovascular (CV) diseases, seem closely related to diabetes microvascular complications. Aspirin represents the most prescribed compound in CV prevention. Aspirin impact o...
Saved in:
| Published in: | Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2020-09, Vol.30 (10), p.1806-1812 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c339t-41ea26ec2d07ccb570ae87ba8f42f1d9a36691e22f08298c3b9847938c17925f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c339t-41ea26ec2d07ccb570ae87ba8f42f1d9a36691e22f08298c3b9847938c17925f3 |
| container_end_page | 1812 |
| container_issue | 10 |
| container_start_page | 1806 |
| container_title | Nutrition, metabolism, and cardiovascular diseases |
| container_volume | 30 |
| creator | Pafundi, Pia Clara Galiero, Raffaele Caturano, Alfredo Acierno, Carlo de Sio, Chiara Vetrano, Erica Nevola, Riccardo Gelso, Aldo Bono, Valeria Costagliola, Ciro Marfella, Raffaele Sardu, Celestino Rinaldi, Luca Salvatore, Teresa Adinolfi, Luigi Elio Sasso, Ferdinando Carlo |
| description | Diabetic retinopathy (DR) is the most common microvascular complication of diabetes. Diabetic macroangiopathies, particularly cardiovascular (CV) diseases, seem closely related to diabetes microvascular complications. Aspirin represents the most prescribed compound in CV prevention. Aspirin impact on DR is still object of debate. As it is already recommended among diabetics at high CV risk, aim of this study was to assess a potential relationship between DR and aspirin therapy, in a type 2 diabetes cohort of patients screened through telemedicine.
NO Blind is a cross-sectional, multicenter, observational study, which involved nine Italian outpatient clinics. Primary endpoint was the assessment of the relationship between aspirin treatment and DR. 2068 patients were enrolled in the study, subsequently split in two subpopulations according to either the presence or absence of DR. Overall, 995 subjects were under aspirin therapy. After adjusting for most common potential confounders, age and gender, aspirin reveals significantly associated with DR (OR: 1.72, 95%CI: 1.58–2.89, p = 0.002) and proliferative DR (PDR) (OR: 1.89, 95%CI: 1.24–2.84, p = 0.003). Association comes lost further adjusting for MACEs (OR: 1.28, 95%CI: 0.85–1.42, p = 0.157) (Model 4) and eGFR (OR: 0.93; 95%CI: 0.71–1.22; p = 0.591) (Model 5).
In this multicenter cross-sectional study including a large sample of outpatients with T2DM, we showed that aspirin was not associated with DR after adjustment for several cardio-metabolic confounders. However, as partially confirmed by our findings, and related to the well-known pro-hemorrhagic effect of aspirin, its use should be individually tailored, even by telemedicine tools.
•The real impact of aspirin use on DR is currently object of debate.•A lack of independent association between aspirin use and DR emerged.•MACEs and DKD are the main confounders of this association. |
| doi_str_mv | 10.1016/j.numecd.2020.06.021 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2429786835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939475320302507</els_id><sourcerecordid>2429786835</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-41ea26ec2d07ccb570ae87ba8f42f1d9a36691e22f08298c3b9847938c17925f3</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMoWKv_wEWWbmbMY2aSuBBq1Voo7UbXIZO506Z0Hiap0H_vlHEtXO7lwjkHzofQPSUpJbR43KftsQFbpYwwkpIiJYxeoAnNFUm4YOoSTYjiKslEzq_RTQh7QrggPJugxSz0zrsWD2Nw5UwJ0Vnsh912vYm7Ew4Qh2f7hJdtcNtdDLj2XYPXG_yyWq5fcYjH6nSLrmpzCHD3d6fo6_3tc_6RrDaL5Xy2SiznKiYZBcMKsKwiwtoyF8SAFKWRdcZqWinDi0JRYKwmkilpealkJhSXlgrF8ppP0cOY2_vu-wgh6sYFC4eDaaE7Bs0ypoQsJM8HaTZKre9C8FDr3rvG-JOmRJ-56b0euekzN00KPXAbbM-jDYYaPw68DtZBa6FyHmzUVef-D_gFiUV3Cg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2429786835</pqid></control><display><type>article</type><title>Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study</title><source>ScienceDirect Freedom Collection</source><creator>Pafundi, Pia Clara ; Galiero, Raffaele ; Caturano, Alfredo ; Acierno, Carlo ; de Sio, Chiara ; Vetrano, Erica ; Nevola, Riccardo ; Gelso, Aldo ; Bono, Valeria ; Costagliola, Ciro ; Marfella, Raffaele ; Sardu, Celestino ; Rinaldi, Luca ; Salvatore, Teresa ; Adinolfi, Luigi Elio ; Sasso, Ferdinando Carlo</creator><creatorcontrib>Pafundi, Pia Clara ; Galiero, Raffaele ; Caturano, Alfredo ; Acierno, Carlo ; de Sio, Chiara ; Vetrano, Erica ; Nevola, Riccardo ; Gelso, Aldo ; Bono, Valeria ; Costagliola, Ciro ; Marfella, Raffaele ; Sardu, Celestino ; Rinaldi, Luca ; Salvatore, Teresa ; Adinolfi, Luigi Elio ; Sasso, Ferdinando Carlo ; on behalf of No Blind Study Group</creatorcontrib><description>Diabetic retinopathy (DR) is the most common microvascular complication of diabetes. Diabetic macroangiopathies, particularly cardiovascular (CV) diseases, seem closely related to diabetes microvascular complications. Aspirin represents the most prescribed compound in CV prevention. Aspirin impact on DR is still object of debate. As it is already recommended among diabetics at high CV risk, aim of this study was to assess a potential relationship between DR and aspirin therapy, in a type 2 diabetes cohort of patients screened through telemedicine.
NO Blind is a cross-sectional, multicenter, observational study, which involved nine Italian outpatient clinics. Primary endpoint was the assessment of the relationship between aspirin treatment and DR. 2068 patients were enrolled in the study, subsequently split in two subpopulations according to either the presence or absence of DR. Overall, 995 subjects were under aspirin therapy. After adjusting for most common potential confounders, age and gender, aspirin reveals significantly associated with DR (OR: 1.72, 95%CI: 1.58–2.89, p = 0.002) and proliferative DR (PDR) (OR: 1.89, 95%CI: 1.24–2.84, p = 0.003). Association comes lost further adjusting for MACEs (OR: 1.28, 95%CI: 0.85–1.42, p = 0.157) (Model 4) and eGFR (OR: 0.93; 95%CI: 0.71–1.22; p = 0.591) (Model 5).
In this multicenter cross-sectional study including a large sample of outpatients with T2DM, we showed that aspirin was not associated with DR after adjustment for several cardio-metabolic confounders. However, as partially confirmed by our findings, and related to the well-known pro-hemorrhagic effect of aspirin, its use should be individually tailored, even by telemedicine tools.
•The real impact of aspirin use on DR is currently object of debate.•A lack of independent association between aspirin use and DR emerged.•MACEs and DKD are the main confounders of this association.</description><identifier>ISSN: 0939-4753</identifier><identifier>EISSN: 1590-3729</identifier><identifier>DOI: 10.1016/j.numecd.2020.06.021</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Aspirin ; Diabetes complications ; Diabetic retinopathy ; Type 2 diabetes</subject><ispartof>Nutrition, metabolism, and cardiovascular diseases, 2020-09, Vol.30 (10), p.1806-1812</ispartof><rights>2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-41ea26ec2d07ccb570ae87ba8f42f1d9a36691e22f08298c3b9847938c17925f3</citedby><cites>FETCH-LOGICAL-c339t-41ea26ec2d07ccb570ae87ba8f42f1d9a36691e22f08298c3b9847938c17925f3</cites><orcidid>0000-0002-9142-7848</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,783,787,27937,27938</link.rule.ids></links><search><creatorcontrib>Pafundi, Pia Clara</creatorcontrib><creatorcontrib>Galiero, Raffaele</creatorcontrib><creatorcontrib>Caturano, Alfredo</creatorcontrib><creatorcontrib>Acierno, Carlo</creatorcontrib><creatorcontrib>de Sio, Chiara</creatorcontrib><creatorcontrib>Vetrano, Erica</creatorcontrib><creatorcontrib>Nevola, Riccardo</creatorcontrib><creatorcontrib>Gelso, Aldo</creatorcontrib><creatorcontrib>Bono, Valeria</creatorcontrib><creatorcontrib>Costagliola, Ciro</creatorcontrib><creatorcontrib>Marfella, Raffaele</creatorcontrib><creatorcontrib>Sardu, Celestino</creatorcontrib><creatorcontrib>Rinaldi, Luca</creatorcontrib><creatorcontrib>Salvatore, Teresa</creatorcontrib><creatorcontrib>Adinolfi, Luigi Elio</creatorcontrib><creatorcontrib>Sasso, Ferdinando Carlo</creatorcontrib><creatorcontrib>on behalf of No Blind Study Group</creatorcontrib><title>Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study</title><title>Nutrition, metabolism, and cardiovascular diseases</title><description>Diabetic retinopathy (DR) is the most common microvascular complication of diabetes. Diabetic macroangiopathies, particularly cardiovascular (CV) diseases, seem closely related to diabetes microvascular complications. Aspirin represents the most prescribed compound in CV prevention. Aspirin impact on DR is still object of debate. As it is already recommended among diabetics at high CV risk, aim of this study was to assess a potential relationship between DR and aspirin therapy, in a type 2 diabetes cohort of patients screened through telemedicine.
NO Blind is a cross-sectional, multicenter, observational study, which involved nine Italian outpatient clinics. Primary endpoint was the assessment of the relationship between aspirin treatment and DR. 2068 patients were enrolled in the study, subsequently split in two subpopulations according to either the presence or absence of DR. Overall, 995 subjects were under aspirin therapy. After adjusting for most common potential confounders, age and gender, aspirin reveals significantly associated with DR (OR: 1.72, 95%CI: 1.58–2.89, p = 0.002) and proliferative DR (PDR) (OR: 1.89, 95%CI: 1.24–2.84, p = 0.003). Association comes lost further adjusting for MACEs (OR: 1.28, 95%CI: 0.85–1.42, p = 0.157) (Model 4) and eGFR (OR: 0.93; 95%CI: 0.71–1.22; p = 0.591) (Model 5).
In this multicenter cross-sectional study including a large sample of outpatients with T2DM, we showed that aspirin was not associated with DR after adjustment for several cardio-metabolic confounders. However, as partially confirmed by our findings, and related to the well-known pro-hemorrhagic effect of aspirin, its use should be individually tailored, even by telemedicine tools.
•The real impact of aspirin use on DR is currently object of debate.•A lack of independent association between aspirin use and DR emerged.•MACEs and DKD are the main confounders of this association.</description><subject>Aspirin</subject><subject>Diabetes complications</subject><subject>Diabetic retinopathy</subject><subject>Type 2 diabetes</subject><issn>0939-4753</issn><issn>1590-3729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLAzEUhYMoWKv_wEWWbmbMY2aSuBBq1Voo7UbXIZO506Z0Hiap0H_vlHEtXO7lwjkHzofQPSUpJbR43KftsQFbpYwwkpIiJYxeoAnNFUm4YOoSTYjiKslEzq_RTQh7QrggPJugxSz0zrsWD2Nw5UwJ0Vnsh912vYm7Ew4Qh2f7hJdtcNtdDLj2XYPXG_yyWq5fcYjH6nSLrmpzCHD3d6fo6_3tc_6RrDaL5Xy2SiznKiYZBcMKsKwiwtoyF8SAFKWRdcZqWinDi0JRYKwmkilpealkJhSXlgrF8ppP0cOY2_vu-wgh6sYFC4eDaaE7Bs0ypoQsJM8HaTZKre9C8FDr3rvG-JOmRJ-56b0euekzN00KPXAbbM-jDYYaPw68DtZBa6FyHmzUVef-D_gFiUV3Cg</recordid><startdate>20200924</startdate><enddate>20200924</enddate><creator>Pafundi, Pia Clara</creator><creator>Galiero, Raffaele</creator><creator>Caturano, Alfredo</creator><creator>Acierno, Carlo</creator><creator>de Sio, Chiara</creator><creator>Vetrano, Erica</creator><creator>Nevola, Riccardo</creator><creator>Gelso, Aldo</creator><creator>Bono, Valeria</creator><creator>Costagliola, Ciro</creator><creator>Marfella, Raffaele</creator><creator>Sardu, Celestino</creator><creator>Rinaldi, Luca</creator><creator>Salvatore, Teresa</creator><creator>Adinolfi, Luigi Elio</creator><creator>Sasso, Ferdinando Carlo</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9142-7848</orcidid></search><sort><creationdate>20200924</creationdate><title>Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study</title><author>Pafundi, Pia Clara ; Galiero, Raffaele ; Caturano, Alfredo ; Acierno, Carlo ; de Sio, Chiara ; Vetrano, Erica ; Nevola, Riccardo ; Gelso, Aldo ; Bono, Valeria ; Costagliola, Ciro ; Marfella, Raffaele ; Sardu, Celestino ; Rinaldi, Luca ; Salvatore, Teresa ; Adinolfi, Luigi Elio ; Sasso, Ferdinando Carlo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-41ea26ec2d07ccb570ae87ba8f42f1d9a36691e22f08298c3b9847938c17925f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aspirin</topic><topic>Diabetes complications</topic><topic>Diabetic retinopathy</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pafundi, Pia Clara</creatorcontrib><creatorcontrib>Galiero, Raffaele</creatorcontrib><creatorcontrib>Caturano, Alfredo</creatorcontrib><creatorcontrib>Acierno, Carlo</creatorcontrib><creatorcontrib>de Sio, Chiara</creatorcontrib><creatorcontrib>Vetrano, Erica</creatorcontrib><creatorcontrib>Nevola, Riccardo</creatorcontrib><creatorcontrib>Gelso, Aldo</creatorcontrib><creatorcontrib>Bono, Valeria</creatorcontrib><creatorcontrib>Costagliola, Ciro</creatorcontrib><creatorcontrib>Marfella, Raffaele</creatorcontrib><creatorcontrib>Sardu, Celestino</creatorcontrib><creatorcontrib>Rinaldi, Luca</creatorcontrib><creatorcontrib>Salvatore, Teresa</creatorcontrib><creatorcontrib>Adinolfi, Luigi Elio</creatorcontrib><creatorcontrib>Sasso, Ferdinando Carlo</creatorcontrib><creatorcontrib>on behalf of No Blind Study Group</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nutrition, metabolism, and cardiovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pafundi, Pia Clara</au><au>Galiero, Raffaele</au><au>Caturano, Alfredo</au><au>Acierno, Carlo</au><au>de Sio, Chiara</au><au>Vetrano, Erica</au><au>Nevola, Riccardo</au><au>Gelso, Aldo</au><au>Bono, Valeria</au><au>Costagliola, Ciro</au><au>Marfella, Raffaele</au><au>Sardu, Celestino</au><au>Rinaldi, Luca</au><au>Salvatore, Teresa</au><au>Adinolfi, Luigi Elio</au><au>Sasso, Ferdinando Carlo</au><aucorp>on behalf of No Blind Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study</atitle><jtitle>Nutrition, metabolism, and cardiovascular diseases</jtitle><date>2020-09-24</date><risdate>2020</risdate><volume>30</volume><issue>10</issue><spage>1806</spage><epage>1812</epage><pages>1806-1812</pages><issn>0939-4753</issn><eissn>1590-3729</eissn><abstract>Diabetic retinopathy (DR) is the most common microvascular complication of diabetes. Diabetic macroangiopathies, particularly cardiovascular (CV) diseases, seem closely related to diabetes microvascular complications. Aspirin represents the most prescribed compound in CV prevention. Aspirin impact on DR is still object of debate. As it is already recommended among diabetics at high CV risk, aim of this study was to assess a potential relationship between DR and aspirin therapy, in a type 2 diabetes cohort of patients screened through telemedicine.
NO Blind is a cross-sectional, multicenter, observational study, which involved nine Italian outpatient clinics. Primary endpoint was the assessment of the relationship between aspirin treatment and DR. 2068 patients were enrolled in the study, subsequently split in two subpopulations according to either the presence or absence of DR. Overall, 995 subjects were under aspirin therapy. After adjusting for most common potential confounders, age and gender, aspirin reveals significantly associated with DR (OR: 1.72, 95%CI: 1.58–2.89, p = 0.002) and proliferative DR (PDR) (OR: 1.89, 95%CI: 1.24–2.84, p = 0.003). Association comes lost further adjusting for MACEs (OR: 1.28, 95%CI: 0.85–1.42, p = 0.157) (Model 4) and eGFR (OR: 0.93; 95%CI: 0.71–1.22; p = 0.591) (Model 5).
In this multicenter cross-sectional study including a large sample of outpatients with T2DM, we showed that aspirin was not associated with DR after adjustment for several cardio-metabolic confounders. However, as partially confirmed by our findings, and related to the well-known pro-hemorrhagic effect of aspirin, its use should be individually tailored, even by telemedicine tools.
•The real impact of aspirin use on DR is currently object of debate.•A lack of independent association between aspirin use and DR emerged.•MACEs and DKD are the main confounders of this association.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.numecd.2020.06.021</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-9142-7848</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-4753 |
| ispartof | Nutrition, metabolism, and cardiovascular diseases, 2020-09, Vol.30 (10), p.1806-1812 |
| issn | 0939-4753 1590-3729 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2429786835 |
| source | ScienceDirect Freedom Collection |
| subjects | Aspirin Diabetes complications Diabetic retinopathy Type 2 diabetes |
| title | Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-11T01%3A36%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aspirin%20in%20a%20diabetic%20retinopathy%20setting:%20Insights%20from%20NO%20BLIND%20study&rft.jtitle=Nutrition,%20metabolism,%20and%20cardiovascular%20diseases&rft.au=Pafundi,%20Pia%20Clara&rft.aucorp=on%20behalf%20of%20No%20Blind%20Study%20Group&rft.date=2020-09-24&rft.volume=30&rft.issue=10&rft.spage=1806&rft.epage=1812&rft.pages=1806-1812&rft.issn=0939-4753&rft.eissn=1590-3729&rft_id=info:doi/10.1016/j.numecd.2020.06.021&rft_dat=%3Cproquest_cross%3E2429786835%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c339t-41ea26ec2d07ccb570ae87ba8f42f1d9a36691e22f08298c3b9847938c17925f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2429786835&rft_id=info:pmid/&rfr_iscdi=true |